Invokana and Ketoacidosis

| Drug Lawsuits

Invokana, which contains the drug ingredient canagliflozin, was approved by the Food and Drug Administration (FDA) in March 2012. It is classified as an SGLT2 inhibitor, which works by reducing blood sugar levels by helping the patient’s kidney’s remove excess sugar through their urine. Other drugs in this class include the brand names Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi.

In May 2015, the FDA issued a warning that SGLT2 inhibitors had been linked to ketoacidosis, a serious buildup of acids, called ketones, in the blood that can be life threatening if left untreated. The condition is caused by an insulin deficiency that forces cells to burn fat for energy instead of glucose, which produces ketones. In diabetic patients, it is also known as diabetic ketoacidosis, or DKA. At that time, the FDA reported 20 cases of ketoacidosis in patients who had used SGLT2 inhibitors.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Respectful, understanding, efficient and compassionate

Beasley Allen is one of the most professional organizations I have ever had the pleasure of working with. They are respectful, understanding, efficient, and above all compassionate. They take the best care of their clients in every way possible. They keep us informed and aware of things involved in their clients cases. Their counsel is stellar in the industry. I would highly recommend them to others in their time of need and I have done so.

—Chad H.